I-PYY to membranes of rat intestinal crypt cells and of CHO cells stably transfected with the rat hippocampal Y 2 receptor cDNA. Similar PYY preference was observed and all analogs exhibited comparable high affinity in both binding assays. The same held true for the specific Y 2 antagonist BIIE0246 with a K i value of 6.5 and 9.0 nM, respectively. BIIE0246 completely abolished the inhibition of cAMP production by PYY in crypt cells and transfected CHO cells. Moreover, the antagonist 1) considerably reversed the PYY-induced reduction of shortcircuit current in rat jejunum mucosa in Ussing chamber and 2) completely abolished the antisecretory action of PYY on vasoactive intestinal peptide (VIP)-induced fluid secretion in rat jejunum in vivo. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) experiments showed that Y 2 receptor transcripts were present in intestinal crypt cells (3 ϫ 10 2 molecules/100 ng RNA T ) with no expression in villus cells, in complete agreement with the exclusive binding of PYY in crypt cells. Finally, a full-length Y 2 receptor was cloned by RT-PCR from rat intestinal crypt cells and also from human small intestine. We conclude that the so-called PYY-preferring receptor mediating inhibition of intestinal secretion is a peripheral Y 2 receptor.
Peptide YY, neuropeptide Y, and pancreatic polypeptide are members of the PP-fold family of peptides (Michel et al., 1998; Gehlert, 1998) . They share important structural and biological similarities but originate from different sources (Gehlert, 1998; Cerda-Reverter and Larhammar, 2000) . PYY is an intestinal hormone released by distal small intestine and colon, whereas NPY is a neurotransmitter in the brain and at the periphery (Gehlert, 1998) . PP is a circulating peptide produced by PP-cells in the endocrine pancreas (Gehlert, 1998) .
It has long been known that a PYY receptor is present in the rat small intestinal epithelium (Laburthe et al., 1986) . It was defined as PYY-preferring because it exhibits a ϳ10-fold higher affinity for PYY than for NPY (Laburthe et al., 1986) . This receptor was shown to be negatively coupled to cAMP production (Servin et al., 1989) and to be located in crypt cells (Voisin et al., 1990) . Thereafter, numerous reports showed a potent inhibition of intestinal electrolyte secretion by PYY (Cox et al., 1988; Voisin et al., 1990; Cox, 1998; Fu-Cheng et al., 1999) , suggesting that agonists acting at this receptor may have potential antidiarrheal value (Laburthe, 1991; Playford and Cox, 1996) . The inhibitory effects on cAMP production (Servin et al., 1989) and electrolyte secretion (Laburthe et al., 1982; Voisin et al., 1990; Eto et al., 1997) in intestine were also shown to be PYY-preferring with PYY being more potent than NPY. The PYY preference has recently been claimed as being a common characteristics of receptors in gastrointestinal epithelia (Holliday et al., 2000) . Although characterized at the biochemical level as a 44-kDa glycoprotein (Voisin et al., 1991) , the intestinal PYY receptor has not been yet cloned. Convincing evidence for the existence of such a receptor is still lacking thereby.
Several receptor subtypes that bind PYY, NPY and/or PP have been cloned (Michel et al., 1998; Ingenhoven and BeckSickinger, 1999; Laburthe et al., 1999) . They are heptahelical G protein-coupled receptors and are referred to as Y receptors (Michel et al., 1998) . Y 1 , Y 2 , and Y 5 receptors have similar affinity to NPY and PYY, whereas Y 4 receptor seems to be specific for PP (Voisin et al., 2000) although there was initial confusion regarding its pharmacological profile (Bard et al., 1995; Lundell et al., 1995 Lundell et al., , 1996 Yan et al., 1996) . A Y 6 receptor has been cloned in mice (Weinberg et al., 1996) but seems to be absent in rats (Burkhoff et al., 1998) . Finally, a putative Y 3 receptor claimed to be specific for NPY has been proposed in rat cardiac ventricular membranes, with NPY 18 -36 being a competitive antagonist (Balasubramaniam and Sheriff, 1990) . However, this putative subtype remains to be cloned (Michel et al., 1998) . Therefore the pharmacology of cloned Y receptors is not fully characterized, whereas potential additional Y receptors, not yet cloned, have been suggested (Blomqvist and Herzog, 1997) .
The pharmacology of the intestinal PYY receptor is clearly different from that of the Y 4 receptor specific for PP or the putative Y 3 receptor specific for NPY (Laburthe et al., 1999) . We demonstrated previously that it is not a Y 5 receptor (Goumain et al., 1998a) . Because it binds with high affinity C-terminal PYY fragments (Laburthe et al., 1986) , including PYY 22-36 , PYY [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , and analogs (Balasubramaniam et al., 2000) , the intestinal PYY receptor is not a Y 1 receptor, which requires the presence of the N terminus of PYY or NPY for high-affinity binding . The ability of the intestinal PYY receptor to accept deletion of the N-terminal domain of PYY makes it Y 2 -like because Y 2 receptors can bind NPY 3-36 or NPY 13-36 with high affinity . However, there are arguments disproving this view: 1) after initial cloning of Y 2 receptor in the central nervous system, Y 2 receptor mRNAs were found in several areas of the brain, but no transcripts could be detected at the periphery (Gerald et al., 1995; Rose et al., 1995; ; 2) the PYY preference displayed by the intestinal receptor (Laburthe et al., 1986) was not consistently reported for the cloned human Y 2 receptors or the native Y 2 receptors (Gehlert, 1998; Ingenhoven and BeckSickinger, 1999) ; 3) recent RT-PCR experiments identified Y 2 receptor mRNA in both intestinal epithelial crypt cells and villus cells (Goumain et al., 1998b) , whereas PYY binding occurs exclusively in crypt cells (Voisin et al., 1990) .
In this context, the present study has been designed to determine whether or not the intestinal PYY receptor is a peripheral Y 2 receptor. We took advantage of two recent advances in this area: 1) the cloning of a rat Y 2 receptor from hippocampus (St Pierre et al., 1998) and 2) the development of a specific Y 2 antagonist (Doods et al., 1999) . We show here that the pharmacological profiles of PYY-preferring receptor from rat crypt cells and rat hippocampal Y 2 receptor stably transfected in CHO cells are identical. We further demonstrated that the Y 2 receptor antagonist BIIE0246 blocks PYY-induced inhibition of cAMP production in isolated crypt cells, PYY-induced decrease of short-circuit current in rat jejunum mucosa, and PYY-induced inhibition of fluid secretion in rat jejunum in vivo. Finally, we showed by quantitative RT-PCR that Y 2 transcripts are exclusively expressed in crypt cells of the jejunum and we cloned a full-length Y 2 receptor cDNA from rat crypt cells that exhibits 100% identity with the sequence of the rat hippocampal Y 2 receptor cDNA.
Experimental Procedures
Materials. Male Wistar rats weighing 250 to 280 g were obtained from Iffa-Credo (Iffa-Credo, Les Oncins, L'Arbresle). They were fed with standard laboratory chow and had free access to tap water. Animal care was according to the Recommendations of the local committee and the National Institutes of Health Guidelines for the Care and the Use of Laboratory Animals, 1985 . The Chinese hamster ovary (CHO) cells were purchased from the European Collection of Cell Cultures (Salisbury, Wiltshire, UK) and cultured in Ham's F12 nutrient mixture (Invitrogen, Leek, The Netherlands) supplemented with 10% fetal calf serum (v/v) (Invitrogen), 100 IU/ml penicillin, and 100 g/ml streptomycin in a humidified atmosphere of 95% air/5% CO 2 at 37°C. Cells were passaged every 3 days in 25-cm 2 plastic culture flasks and used between the 4th and 25th passages. Analogs and fragments of rat (r) NPY 1-36 , porcine (p) NPY 3-36 , rNPY , and the Y 1 antagonist/Y 4 agonist 1229U91 (also known as homodimeric Ile-Glu-Pro-Dpr-Tyr-Arg-Leu-Arg-Tyr-CONH 2 or GW1229) were purchased from Neosystem (Strasbourg, France) or Peninsula Laboratories (Belmont, CA). Rat N-␣-acetyl-PYY [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and N-␣-acetyl-PYY 25-36 were synthesized as described previously (Balasubramaniam et al., 2000) . The Y 2 -specific antagonist BIIE0246 was provided by Boehringer Ingelheim Pharma (Biberach, Germany) (Doods et al., 1999) . Iodine-125 was incorporated into the tyrosine 36 residue of pPYY using the chloramine T method and purified as described previously (Voisin et al., 1991) . The specific activity was assumed to be of the theoretical value (2200 Ci/mmol). The eucaryotic vector pcDNA3 was purchased from Invitrogen (Cergy Pontoise, France).
Stable Transfection of CHO Cells and Related Protocols. Full-length rat Y 2 receptor cDNA cloned in hippocampus (St. Pierre et al., 1998) was provided by author H. H. The cDNA was subcloned into the pcDNA3 expression vector, which contains the selectable geneticin gene. The recombinant plasmid was transfected into the CHO cell line by electroporation. Briefly, CHO cells were rinsed in phosphate-buffered saline, removed from the culture dish using 0.5-ml versene/trypsin (5 min at 37°C) and pelleted by centrifugation. CHO cells were resuspended in phosphate-buffered saline at a concentration of 10 6 cells/ml and then 500 l of cell suspension (0.5 ϫ 10 6 cells) were transferred in an electroporation cuvette together with 15 g of rat Y 2 cDNA/pcDNA3 and 15 g of salmon sperm DNA as carrier. After gentle shaking for 5 min at 4°C, electroporation was performed (330 V, 500 F) using a Electroporator II (Invitrogen). Transfected cells were then resuspended in culture medium, transferred into 150-mm Petri dishes, and incubated for 48 h at 37°C. Two days after transfection, cells were selected through the addition of G418 Geneticin, at a final concentration of 1 mg/ml for 3 weeks. Resistant transfected cells were cloned by limiting dilution. Briefly, transfected CHO cells suspension was distributed to a microtest 96-well plate, at a mean ratio of 0.25 cell/well. Cells grown in wells observed to initially contain one cell were subsequently transferred to larger culture vessels. Among the 13 clones obtained, clone 11 was selected on the basis of its binding capacity for PYY, which was similar to that found in rat intestinal crypt cells (see Results). Clone 11 cells were then cultured in standard culture medium (see above) supplemented with G418 Geneticin (400 g/ml) and were routinely passaged every 3 days. Stably transfected cells (clone 11) were grown in 75-cm 2 plastic culture flasks for 4 to 5 days. Cell membranes were prepared for binding experiments as follows: cells were washed three times with 0.13 M phosphate-buffered saline, pH 7.4, harvested using a rubber policeman, and centrifuged at 2000g for 5 min at 4°C. The cell pellet was then exposed for 30 min to hypoosmotic 5 mM HEPES buffer, pH 7.4, as described previously (Voisin et al., 1990) . The resulting broken cell suspension was centrifuged at 20,000 g for 15 min, washed with 20 mM HEPES buffer, pH 7.4, pelleted and stored at Ϫ80°C until use. This particulate fraction will be referred to as membrane preparation.
Transient Transfection of CHO Cells with the Human Y 2 Receptor cDNA. CHO cells were transiently transfected with a full-length human Y 2 receptor cDNA inserted in pcDNA3 expression vector, by using an electroporation method as described above (see Stable Transfection of CHO Cells). Transfected cells were then resuspended in culture medium, transferred into 150-mm Petri dishes, and cultured for 48 h at 37°C. Cell membranes were then prepared for binding experiments as described above.
Preparation of Intestinal Epithelial Cells and Related Protocols. Jejunum was removed after decapitation of rats and crypt cells were separated from villus cells by shaking the everted intestine for successive periods in a dispersing solution containing EDTA as described (Voisin et al., 1990) . Cell fractions were first characterized by optical microscopy. Villus sheets were morphologically different from crypts, which had the shape of sticks of cells. Villus cells were then characterized by their brush border-associated alkaline phosphatase activity (Voisin et al., 1990) . Enzyme activity was six times higher in villus cells than in crypt cells, as reported previously (Voisin et al., 1990) H]thymidine (50 Ci), which had been injected to rats 2 h before death (Voisin et al., 1990) . Crypt cells clearly incorporated 30 times more radioactivity than villus cells [i.e., 6830 Ϯ 420 versus 210 Ϯ 73 dpm/0.1 mg of protein (five experiments). Rat colonic epithelial cells were isolated as described previously (Laburthe et al., 1986) . Cells were used immediately for RNA extraction (see below). The crypt cell fraction was also used to prepare crude membranes as described previously (Voisin et al., 1990) . Briefly, crypt cells were homogenized with the use of a Waring blender in 0.25 M sucrose buffered with 10 mM triethanolamine, pH 7.5, containing 5 mM EDTA. After centrifugation at 2,600 g for 10 min, the supernatant was centrifuged at 20,000 g for 15 min. The resulting pellet was washed in 20 mM HEPES buffer, pH 7.5, repelleted, and stored at Ϫ80°C until use (Voisin et al., 1990) .
Binding Assay. Binding of 125 I-peptide YY to membranes prepared from crypt cells or transfected cells was carried out as described previously (Voisin et al., 1990) . Briefly, membranes (200 g of protein/ml) were incubated at 15°C for 120 min in 250 l of incubation buffer [20 mM HEPES, pH 7.4, 2% (w/v) bovine serum albumin] containing 0.05 nM 125 I-PYY with or without unlabeled PYY or other competitors. At the end of incubation, aliquots (150 l) of membranes were mixed with 150 l of ice-cold incubation buffer. Bound and free peptides were separated by centrifugation at 20,000 g for 10 min, and membrane pellets were washed twice with 10% (w/v) sucrose in 20 mM HEPES. All binding data were analyzed using PRISM 3.0 software (GraphPad Software, San Diego, CA). The constant K i for the inhibition of 125 I-peptide YY binding by unlabeled competitors was calculated from the concentration of unlabeled competitor that produces 50% inhibition (IC 50 ) of the specific 125 I-peptide YY binding using the following relation:
where K d is the dissociation constant and L the concentration of 125 I-peptide YY. K i values are given as geometric means with 95% confidence limits in parentheses from 3 to 15 experiments.
cAMP Assay. Isolated intestinal crypt cells at 200 g protein/ml were incubated under continuous agitation for 45 min at 15°C in 0.5 ml of phosphate-buffered saline, pH 7.0, containing 1.4% (w/v) bovine serum albumin, 0.1% bacitracin, and 0.2 mM 3-isobutyl-1-methylxanthine (IBMX) as described previously (Servin et al., 1989) . PYY or NPY were added together with the most potent physiological stimulant of cAMP production in enterocytes (e.g., VIP). The reaction was initiated by adding cells and was stopped after 45 min by adding 50 l of 11 M perchloric acid. After centrifugation for 10 min at 4,000g, the cAMP present in the supernatant was succinylated, and its concentration was measured by radioimmunoassay as described previously (Laburthe et al., 1982) . The same method was used for cAMP assay on CHO clone 11 cells, but cultured cells were incubated at a final concentration of 1.5 ϫ 10 6 cells/ml, and forskolin was used to stimulate cAMP production.
Ussing Chamber. The jejunum (5 cm distal to the ligament of Treitz) from 24 h-fasted rats was dissected out and rinsed in cold KRB solution (see below) to remove luminal contents. The mesenteric border was carefully stripped off and the serosa and longitudinal muscle/myenteric plexus were stripped away using forceps. Intestine was then opened along the mesenteric border and placed between the two halves of a Ussing chamber (exposed area: 0.63 cm 2 ). The tissues were bathed with 6 ml of KRB solution on each side and maintained at 37°C. The KRB bicarbonate solution (115.4 mM NaCl, 5 mM KCl, 1.2 mM MgCl 2 , 0.6 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 1.2 mM CaCl 2 , and 10 mM glucose) was gassed with 95% O 2 /5% CO 2 and kept at constant temperature of 37°C, pH 7.4. Electrogenic ion transport was monitored continuously as the shortcircuit current (Isc) by using an automated voltage-clamp apparatus (DVC 1000; WPI, Aston, England) linked through MacLab 8 to a Macintosh computer. Every 50 s, the tissue was automatically clamped at Ϯ 1 mV for 5 s to calculate the electrical conductance according to Ohm's law. Results are expressed as the intensity of the Isc (microAmperes/square centimeter) or as the difference (⌬Isc) between the Isc measured within 10 min after addition of the compounds and the basal Isc (measured just before addition of the compound). Stock solution of PYY, VIP, and BIIE0246 were prepared in 0.9% NaCl containing 0.3% bovine serum albumin to limit peptide adherence to glassware, stored frozen at Ϫ20°C and thawed immediately before use. Working solutions were prepared by serial dilution of the stock solution in KRB to achieve final concentration in the range 10 Ϫ6 to 10 Ϫ9 M in the Ussing chamber compartments. All solutions were added as 100-l samples to the serosal bath.
In Vivo Studies. Jejunal ligated loops were prepared in 24 hfasted rats as described in detail by Chariot et al. (2000) . Briefly, in pentobarbital-anesthetized rats (50 mg/kg, intraperitoneal), closed loops of proximal jejunum (10 cm long) were tied off and filled at time 0 with 1 ml of 0.9% saline. Care was taken during the loop preparation to preserve the marginal artery of the bowel from damage. The loops were then returned to the abdomen. Their normal anatomic placement was maintained as far as possible, and the abdominal wall was closed. After 30 min, the rats were killed, the loops were cut off, and the amount of fluid remaining in the lumen was measured, which allowed us to calculate the net water flux. Under these conditions, jejunal net water fluxes were negative, indicating a net absorption, which will be designated below as basal net water flux. To evidence more easily the antisecretory effect of PYY, the basal absorption was counteracted with VIP (100 g/kg/h) infused intravenously (saphenous vein) at 2.5 ml/h for 30 min (from t ϭ 0 to t ϭ 30 min). This concentration was chosen from previous experiments as producing a net secretion in our experimental conditions. The net water flux measured under VIP infusion is designated below as "VIP-stimulated net water flux". PYY was administered as an intravenous infusion of 300 pmol/kg/h beginning 15 min before starting the VIP infusion (from t ϭ Ϫ15 to t ϭ 30 min). To analyze the specific mechanisms involved in the effect of PYY, the Y 2 or Y 1 receptor antagonists (30 nmol/kg/h) were injected with PYY. These concentrations of antagonist drugs were chosen based on the data described in this article. Appropriate control groups were set up to determine the effect of the antagonists on basal net water flux. The effect of the antagonist was determined by comparing the net water flux with and without antagonist after infusion of saline, and of VIP ϩ PYY, by analysis of variance followed by a Dunnett's test. Differences with P Ͻ 0.05 were considered significant.
RNA Extraction and Quantitative RT-PCR of Y 2 Receptors. Total RNA was extracted from rat epithelial crypt or villus cells using RNAxel reagent (Goumain et al., 1998b) . Total RNA was quantified at 260/280 nm, and the integrity of the samples was checked by 1% agarose gel electrophoresis. Aliquots were stored in sterile microcentrifuge tubes at Ϫ80°C until use. Quantitative RT-PCR of Y 2 receptors was developed as described previously (RouetBenzineb et al., 1999) . Design of sense and anti-sense primers for rat Y 2 receptor was performed using the previously published rat brain Y 2 receptor cDNA sequence (St. Pierre et al., 1998) . The rat Y 2 receptor primers are 5Ј-AAA TGG GTC CAG TTT TGT GCC-3Ј (sense) and 5Ј-TGC CTT CGC TGA TGG TAA TGG-3Ј (anti-sense). A specific internal DNA standard was obtained by amplification of foreign DNA fragment issued from the ampicillin resistance gene in the pcDNA3 plasmid using composite primers rY 2 -Amp (sense, 5Ј-AAA TGG GTC CAG TTT TGT GCC TCC AGA TTT ATC AG-3Ј; antisense, 5Ј-TGC CTT CGC TGA TGG TAA TGG CAA GAG CAA CTC GGT C-3Ј). DNase-treated RNA T (2 g) from each individual cell fractions (crypt, villus, and colon) was reverse-transcribed into cDNA for 1-h incubation period at 37°C in a reaction medium composed of 30 l of (final concentration) 1.5 M oligo(dT 15 ), 0.5 mM dNTP, 13.3 U/l Moloney murine leukemia virus reverse transcriptase (Invitrogen) in 10 mM Tris-HCl, pH 8.3, 75 mM KCl, and 0.6 mM MgCl 2 . For each PCR, 1 l of the first-strand cDNA and 1 l of internal DNA standard (103 molecules) were added to 48 l of a mixture containing 20 pmol/l of each Y 2 primer; 200 M each dATP, dCTP, dTTP, and dGTP; 50 mM KCl; 10 mM Tris-HCl, pH 9.0; 1.5 mM MgCl 2 , 0.3 l of [␣-
32 P]dCTP (3 Ci/nmol), and 0.5 U of Thermus aquaticus thermostable DNA polymerase. PCR amplification was performed using thermocycler set for 25 cycles of 1-min denaturation at 94°C, 1-min annealing at optimal Tm (60°C), and 1-min extension at 72°C. The last amplification was followed by a final 10-min elongation step at 72°C. PCR fragments were analyzed by electrophoresis in 4% polyacrylamide gel with 1ϫ TBE (100 mM Tris, 90 mM boric acid, and 1 mM EDTA) as running buffer. The quantities of amplified internal standard or amplified target RNA T in each tube were compared by autoradiography and scanning of bands with a Hewlett Packard ScanJet 6100C Scanner densitometer. Each Y 2 amplicon was characterized by specific restriction enzyme digestion using BglII enzyme. The expected fragments were resolved by 4% PAGE with 1ϫ TBE in the presence of molecular mass DNA markers. Bands were cut off the gel and the radioactivity of each band was counted by liquid scintillation spectrometry. Bands were then quantified by comparison with the amplified internal standard. Primers for rat ␤-actin, taken as a control for housekeeping protein, were used.
Rat Intestinal Y 2 Receptor Cloning. A total of 10 g of rat crypt DNase-treated RNA was reverse-transcribed as described above, and 5 l of the resulting cDNA mixture was submitted to PCR using specific primers. Five oligonucleotides, chosen from rat brain Y 2 cDNA cloned sequence (St. Pierre et al., 1998) , were used for PCR (see below) on rat crypt cDNA using the following conditions: 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C for 25 cycles using Taq polymerase (ATGC, Noisy-le-Grand, France). PCR products including the expected full-length rat crypt Y 2 cDNA (1147 bp) were cloned using the pGEMT-Easy kit (Promega, Charbonnieres, France) and sequenced by Genome Express (Grenoble, France). Oligonucleotides primers used for RT-PCR-based cloning strategy of the rat intestinal Y 2 receptor were the following: oligo 1 (sense, 1-27) 5Ј-ATG GGC CCA TTA GGT GCA GAG GCA GAT-3Ј; oligo 2 (sense, 51-71) 5Ј-AGT GGA ACT CTA TGG GTC GGG-3Ј; oligo 3, (sense, 350-371) 5Ј-AAA TGG GTC CAG TTT TGT GCC-3Ј; oligo 4 (antisense, 791-770) 5Ј-TGC CTT CGC TGA TGG TAA TGG-3Ј; oligo 5 (antisense, 1147-1127) 5Ј-CTT ACA CGT TGG TGG CCT CTG 3Ј Human Intestinal Y 2 Receptor Sequencing. A total of 100 ng of QUICK-clone cDNA (CLONTECH Laboratories, Palo Alto, CA) from human small intestine were submitted to PCR using specific human primers. Four oligonucleotides, chosen from the human brain Y 2 receptor cDNA sequence (Rose et al., 1995) , were used for PCR under the following conditions: 1 min at 94°C, 1 min at 58°C, and 1 min at 72°C for 35 cycles using Taq polymerase (ATGC). Two PCR products of 791 bp and 797 bp, including a 442-bp overlapping sequence, were sequenced by Genome Express (Grenoble, France). Oligonucleotides primers used for PCR were the following: oligo A (sense, 1-23) 5Ј-ATG GGT CCA ATA GGT GCA GAG GC-3Ј; oligo B (sense, 350-371) 5Ј-AAA TGG GTC CTG TCC TGT GCC-3Ј; oligo C (antisense, 791-770) 5Ј-TGC CTT CGC TGA TGG TAG TGG-3Ј; oligo D (antisense, 1147-1127) 5Ј-CTT AGA CAT TGG TAG CCT CTG-3Ј.
Results
In a first set of experiments, we compared the pharmacological profiles of PYY receptor in membranes from rat intestinal crypt cells and CHO cells stably transfected with the rat brain Y 2 receptor cDNA. Scatchard analysis of the competitive inhibition of (Table 1) . Moreover, PYY 3-36 , NPY 3-36 , NPY 13-36 , or C2-NPY, which are considered typical Y 2 agonists (Gehlert, 1998) , clearly exhibited similar high affinity for the rat brain recombinant Y 2 receptor and the rat crypt cell PYY receptor (Table 1) . Conversely, N-␣-Ac-PYY [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and N-␣-Ac-PYY [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , which are known to have high affinity to the rat cryptic PYY receptor (Balasubramaniam et al., 1993 (Balasubramaniam et al., , 2000 Goumain et al., 1998a) and to behave as potent antisecretory agents in rat intestine (Balasubramaniam et al., 1993) , also have high affinity for the rat brain Y 2 receptor (Table 1) (Yan et al., 1996) has very low affinity, if any, for both receptors (Table 1) . From these data, it could be concluded that the most selective receptor agonists currently available do not discriminate between the rat intestinal PYY receptor and the recombinant rat brain Y 2 receptor. We also investigated the effect of BIIE0246 which is a new specific Y 2 receptor antagonist (Dumont et al., 2000) , on 125 I-PYY binding (Fig. 1 ). It appears that BIIE0246 competes with tracer Fig. 1) with a K i of 6.5 nM (95% confidence interval, 2.3-18.9) and 9 nM (6.7-12.2), respectively. In contrast, the Y 1 receptor antagonist 1229U91 (tested at concentrations up to 1 M), also considered a Y 4 receptor agonist (Gehlert, 1998) , failed to compete with 125 I-PYY for binding to membranes from crypt cells or transfected CHO cells (data not shown).
Further experiments investigated the action of BIIE0246 on the inhibition of cAMP production by PYY. As shown in Fig. 2 , PYY inhibits cAMP production in intact crypt cells or transfected CHO cells with an EC 50 value of 3.8 nM (95% confidence interval, 0.5-25.0) and 15.5 nM (6.9 -31.2), respectively. Addition of the Y 2 receptor antagonist BIIE0246 at 1 M completely abolished the inhibitory action of PYY in both crypt cells and transfected CHO cells (Fig. 2) . Moreover, it was verified that increasing concentrations of BIIE0246 from 0.1 nM to 1 M did antagonize the inhibitory effect of 0.1 M PYY (Fig. 3) in a concentration-dependent manner, which represents 90% of the maximal inhibition that can be evoked by PYY (Fig. 2) .
If the intestinal cryptic PYY receptor is a Y 2 receptor, as suggested by the data described above, then the Y 2 receptor antagonist BIIE0246 should antagonize the inhibitory effect of PYY on electrolyte secretion in rat small intestine. This was investigated here both in vitro and in vivo. First we examined the action of BIIE0246 on short-circuit current (Isc) in the Ussing chamber model. PYY (10 or 100 nM) was added to the serosal side of rat jejunum mounted in Ussing chamber after a 30-min basal state was reached (Isc ϭ 70.6 Ϯ 5.3 A/cm 2 ; conductance ϭ 24.3 Ϯ 0.9 mS/cm 2 , n ϭ 20). Basal Isc dropped significantly (p Ͻ 0.01) in response to either concentration of PYY (Fig. 4 ) without significant change in tissue conductance (not shown). Maximal decrease of Isc in response to 10 nM PYY (⌬Isc ϭ Ϫ26.4 Ϯ 1.6 A/cm 2 , n ϭ 4) or 100 nM PYY (⌬Isc ϭ Ϫ36.7 Ϯ 7.8 A/cm 2 , n ϭ 4) was reached within 6 to 8 min when Isc slowly began to increase for another 10 to 15 min (Fig. 4, B and C) . Addition of 1 M BIIE0246 alone had no effect on Isc (Fig. 4A ) or tissue con- ductance (not shown). When BIIE0246 was added together with either 10 or 100 nM PYY, the maximal decrease of Isc in response to PYY was reduced significantly: ⌬Isc ϭ Ϫ6.8 Ϯ 1.9 A/cm 2 (n ϭ 5, p Ͻ 0.01 versus PYY alone) and Ϫ17.9 Ϯ 4.6 A/cm 2 (n ϭ 4, p Ͻ 0.01 versus PYY alone), respectively (Fig.  4, B and C) . In addition, BIIE0246 also induced a rapid return to basal Isc value that was achieved in 8 to 10 min after maximal decrease [i.e., significantly shorter than with 10 or 100 nM PYY alone (p Ͻ 0.05)]. The action of BIIE0246 in Ussing chamber experiments led us to investigate its effect on net fluid secretion in the rat jejunum in vivo. For that purpose, we studied the action of BIIE0246 on the antisecretory effect of PYY on jejunal net water flux across rat jejunal ligatured loop, stimulated by VIP. In basal conditions, the jejunal mucosa demonstrated a large absorptive flux (Fig. 5) : Ϫ39.8 Ϯ 4.8 l/cm/30 min, which was reverted to secretion: 36.8 Ϯ 2.7 l/cm/30 min (P Ͻ 0.001) by 100 g/kg/h VIP. The secretory effect of VIP was inhibited by 300 pmol/kg.h PYY: 11.7 Ϯ 3.0 l/cm/30 min (Fig. 5, lane VIP ϩ PYY) . The effect of BIIE0246, was studied first on basal, then against PYY. We showed that 30 nmol/kg/h of BIIE0246 reversed by 100% the PYY inhibition of VIP-stimulated secretion (P Ͻ 0.001) (Fig. 5 , lane VIP ϩ PYY ϩ BIIE0246). BIIE0246 alone did not change basal net water flux (Fig. 5, lane BIIE0246) . Nor did it change the VIP-induced secretion (Fig. 5, lane VIP ϩ  BIIE0246) .
The rat intestinal PYY-preferring receptor is expressed in crypt cells in which hydroelectrolytic secretion is believed to take place (Voisin et al., 1990) , whereas a very low amount of PYY receptor, if any, is detected in villus cells (Voisin et al., 1990) . However, previous RT-PCR studies using human Y 2 receptor primers previously identified transcripts in both crypt cells and villus cells, an observation that apparently disagreed with functional data (Goumain et al., 1998b) . Therefore, we investigated here the expression of Y 2 receptor transcripts in isolated crypt cells and villus cells by quantitative RT-PCR using rat Y 2 receptor primers chosen in the recently available rat brain Y 2 receptor sequence (St. Pierre et al., 1998) . A single amplicon of the expected size (442 bp) was observed with RNA extracted from rat crypt cells (Fig.  6A) . Characterization of RT-PCR product by the restriction enzyme BglII yielded two fragments (Fig. 6B ) of expected sizes (315 and 127 bp) strongly supporting that the amplification product corresponded to Y 2 receptor sequence. For evaluation of Y 2 receptor mRNA levels, quantitative RT-PCR of Y 2 receptor was carried out on rat jejunal crypt or villus cells RNA T (total RNA) together with coamplification with 10 3 molecules of specific internal standard DNA (Fig. 6A ). Two serial amplicons of the expected sizes were obtained (i.e., 442 bp for Y 2 receptor cDNA and 489 bp for internal standard cDNA). After RT-PCR using Y 2 receptor primers, a labeled band of 442 bp was observed in rat jejunal crypt cells, whereas no band could be detected in rat jejunal villus cells (Fig. 6A, lanes 2 and 4) . The presence of PCR products for rat ␤-actin taken as a control for a housekeeping gene, was observed in all cell preparations (Fig. 6A, bottom) . The evaluation of Y 2 receptor mRNA level in crypt cells using quantitative RT-PCR showed that 3 ϫ 10 2 mRNA molecules/100 ng RNA T were expressed in crypt cells, whereas no transcript could be detected in villus cells under the same experimental conditions. These data supported that Y 2 receptor mRNA was mainly expressed in rat jejunal crypt cells with no significant expression in rat jejunal villus cells. This distribution is identical to the distribution of 125 I-PYY binding in isolated epithelial cells from rat crypt and villus (Voisin et al., 1990) . Because no 125 I-PYY binding or inhibition of cAMP production by PYY could be observed in epithelial cells isolated from rat colon (Laburthe et al., 1986; Servin et al., 1989) , similar RT-PCR experiments were also carried out on RNA T isolated from rat colonic epithelial cells. No Y 2 receptor transcript could be detected either in colon epithelium (Fig.  6) , further supporting the validity of our data.
The RT-PCR experiments described above identified the prevalent expression of Y 2 receptor transcripts in crypt cells but did not strictly establish the identity between the Y 2 receptor cloned in rat brain (St. Pierre et al., 1998 ) and a Y 2 receptor present in rat crypt cells. Indeed, the primers used encompassed only a portion of the rat brain Y 2 cDNA receptor sequence from 350 to 791 corresponding to residues 118 to 263 in the receptor protein sequence (381 amino acids, full length). Therefore, we performed additional RT-PCR experiments on RNA T extracted from rat crypt cells using several other couples of primers including a couple of primers that fully overlap the Y 2 receptor sequence determined in rat brain (see Experimental Procedures). Single PCR products of the expected sizes were obtained for every oligonucleotide combinations (Fig. 7) . Each of these PCR products was subcloned and sequenced, including the full-length sequence expected with the combination of oligo 1 and oligo 5 (see Fig. 7 ). The obtained full-length nucleotide sequence for the rat intestinal Y 2 receptor and its deduced amino acid sequence are shown on Fig. 8 . Comparison of the nucleotide sequence of this rat intestinal Y 2 receptor with that of the cloned rat brain Y 2 receptor (St. Pierre et al., 1998 ) revealed 100% identity. The same held true for other PCR products obtained, which also exhibited 100% identity with the corre- sponding sequences of the rat brain Y 2 cDNA. Because several PCR products were cloned and sequenced, it can be concluded that a peripheral Y 2 receptor identical to the brain Y 2 receptor does exist in the rat intestinal epithelial crypt cells.
To extend our observations to human intestine, we cloned by PCR a human Y 2 receptor from a human small intestinal cDNA library using brain Y 2 receptor oligonucleotides. The PCR products obtained (Fig. 9A) fully overlapped the Y 2 receptor sequence. Sequencing the two PCR products (data not shown) revealed 100% identity between the human Y 2 receptors in small intestine and brain (Gerald et al., 1995; Rose et al., 1995) . These data indicated that a Y 2 receptor does exist in human small intestine. Binding experiments carried out with the human Y 2 receptor transiently expressed in CHO cells (Fig. 9B) 
Discussion
A very early description of a receptor for PYY and NPY was the characterization of specific binding of 125 I-PYY to rat intestinal epithelial cells (Laburthe et al., 1986) . The term of PYY-preferring receptor was used at that time because PYY was 5 to 10 times more potent than NPY (Laburthe et al., 1986; Laburthe, 1991) . Further studies on PYY-induced inhibition of cAMP production in intestinal cells (Servin et al., 1989) and PYY-induced inhibition of intestinal water and electrolytes secretion in various in vitro and in vivo models (Cox et al., 1988; Cox and Cuthbert, 1990; Balasubramaniam et al., 1993 Balasubramaniam et al., , 2000 confirmed the PYY preference. This property has recently been claimed as being common to receptors in gastrointestinal epithelia (Holliday et al., 2000) . However, it could not be considered the hallmark of an additional Y receptor subtype, because the preference is of small magnitude and a PYY-preferring receptor has not been cloned. In this context, the present study provides strong arguments supporting that the historical PYY-preferring receptor in rat intestinal epithelium is a peripheral Y 2 receptor.
Although Y 2 receptor was cloned in 1995 in humans (Gerald et al., 1995; Rose et al., 1995) , no Y 2 receptor cDNA had been isolated in rats until recently (St. Pierre et al., 1998) . Because there are important pharmacological differences between species for Y receptors (Gehlert, 1998) , the pharmacological profile of the rat intestinal PYY receptor could not be compared directly with that of the Y 2 receptor from humans. In this work, a CHO cell clone stably expressing the rat hippocampal Y 2 receptor was developed. It displayed binding parameters similar to that of the PYY receptor in rat crypt cells in terms of binding capacity and dissociation constant for PYY, allowing direct comparison of receptors from the two sources. First, it could be noted that the PYY preference was also observed for the recombinant rat Y 2 receptor expressed (Michel et al., 1998) PYY 3-36 , PYY 13-36 , NPY 3-36 , and NPY 13-36 or the very short PYY analogs acting at the intestinal PYY receptor, N-␣-AcPYY [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and N-␣-AcPYY 25-36 , could not discriminate between the two receptors (see Table  1 ). Finally, the Y 2 receptor antagonist BIIE0246 displayed identical affinity for the rat intestinal PYY receptor and the recombinant rat Y 2 receptor. This first set of experiments supported the idea that the intestinal PYY-preferring receptor is indistinguishable from a Y 2 receptor at the binding level.
The development of the potent and selective Y 2 receptor antagonist BIIE0246 (Dumont et al., 2000) provided the opportunity to further characterize PYY receptor-mediated proximal and distal responses in small intestine. We showed in this work that BIIE0246 blocked PYY-induced inhibition of cAMP production in isolated jejunal crypt cells, PYY-induced decrease of short-circuit current in rat jejunum mucosa mounted in Ussing chamber, and PYY-induced inhibition of fluid secretion in rat jejunum in vivo. This is in line with the high-affinity binding of BIIE0246 to PYY receptor in intestinal crypt cells and supports that an epithelial Y 2 receptor mediates, at least in part, the antisecretory action of PYY in small intestine (Fu-Cheng et al., 1999) . The Y 2 receptor antagonist BIIE0246 completely blocked the long-term (Ͼ10 min) effect of PYY on short-circuit current in the Ussing chamber assay but only partially blocked the short-term effect (Ͻ10 min) of the peptide (see Fig. 4 ). This is in contrast to the total inhibition seen in other assays including the cAMP assay in vitro (see Fig. 2 ) and the intestinal secretion assay in vivo (see Fig. 5 ). Although it may be suggested that the data obtained in the Ussing chamber assay did not support the idea of the sole mediation of PYY effect via a Y 2 receptor, the in vivo assay clearly indicated a Y 2 receptormediated antisecretory action of PYY in rat small intestine. Because the cAMP assay in vitro and the secretion assay in vivo were carried out over 45-and 30-min periods, respectively, it can be suggested that the partial effect of BIIE0246 over Ͻ 10 min period in the Ussing chamber assay is related to differences in the time course of action of BIIE0246 and PYY that were no longer observed over long incubation periods. Previous studies have shown that PYY and NPY act upon epithelia of the rat small intestine causing a reduction in short-circuit current that is not sensitive to tetrodotoxin (TTX) and is thereby not neurally mediated (Cox et al., 1988) . However, this has not been confirmed by Fu-Cheng et al. (1999) , who claimed that TTX and several other neural antagonists did reduce PYY effect in the rat jejunum in vitro. Furthermore, other in vivo studies indicated that the PYYinduced inhibition of rat small intestinal fluid secretion can be abolished, at least in part, by TTX or hexamethonium, suggesting neuronal mediation (Souli et al., 1997) . The respective contribution of epithelium and neurons in the inhibition of intestinal secretion by PYY certainly deserves further investigation, but our data showing that BIIE0246 completely blocked the action of PYY in isolated crypt cells, in jejunal mucosa in vitro, and in rat jejunum in vivo support the idea that all the actions of PYY on inhibition of fluid secretion in rat small intestine are mediated by Y 2 receptors. In this context, it is worth pointing out that neurally mediated action of PYY on inhibition of fluid secretion may be prevalent in humans . While this work was in progress, we were very interested in the inactivation of Y 2 receptor in mice (Naveilhan et al., 1999) because availability of Y 2 Ϫ/Ϫ mice could have been a clue to our present studies. However, as we were testing Y 2 Ϫ/Ϫ mice for expression of PYY-preferring receptor, we observed that intestinal epithelial cells from normal mice did not exhibit any 125 I-PYY binding (unpublished data). This was in agreement with the absence of effect of PYY on short-circuit current (Isc) in jejunal segment of BALB/c mice mounted in Ussing chamber (authors' unpublished observations). This observation further highlights the issue of species difference in the expression of receptors in the digestive tract and indicates that Y 2 Ϫ/Ϫ mice could not help in solving the problem raised by the present study.
We reasoned that if Y 2 receptor were responsible for PYY binding in rat intestinal epithelium, we should find a good correlation between the expression of Y 2 receptor mRNA and functional studies of PYY binding or PYY-induced inhibition of cAMP production in intestinal epithelial cells. However, previous studies using RT-PCR identified Y 2 transcripts in crypt cells and villus cells from rat small intestine and in rat colon epithelial cells (Goumain et al., 1998b) , whereas PYY binding (Laburthe et al., 1986; Voisin et al., 1990) and PYYinduced inhibition of cAMP production (Servin et al., 1989; Voisin et al., 1990 ) could be only observed in small intestinal crypt cells. To document this issue, we developed here quantitative RT-PCR for Y 2 receptor mRNA. The data clearly demonstrated that under our experimental conditions in which 3 ϫ 10 2 Y 2 receptor mRNA molecules/100 ng RNA T were measured in crypt cells, no transcript could be detected in villus cells or colon epithelial cells. Therefore, there is an excellent correlation between the expression of Y 2 receptor mRNA and 125 I-PYY binding in the different epithelial cell populations isolated from rat small intestine and colon. Previous amplification conditions (35 cycles using 2.5 g RNA T ) most probably detected traces of Y 2 receptor mRNA in villus cells or colon epithelial cells (Goumain et al., 1998b) , whereas the present conditions (25 cycles using 0.1 g RNA T ) did not.
To provide definitive evidence of the existence of Y 2 receptor in rat intestinal crypt cells, full-length Y 2 receptor cDNAs were cloned by RT-PCR from RNA T isolated from these cells. The four clones isolated in separate experiments exhibited 100% identity with the rat hippocampal Y 2 receptor cDNA (St. Pierre et al., 1998) . Neither fragment of Y 2 receptors that were amplified using several couples of primers (see Fig. 7 ) exhibited difference with the rat hippocampal Y 2 receptor sequence. Therefore, it could be concluded that Y 2 receptor does exist in rat crypt cells with no evidence for variants in our experiments. This rat Y 2 receptor exhibits PYY preference in crypt cells or after transfection in CHO cells, whereas previously cloned Y 2 receptors from human nervous tissues exhibited very small PYY preference when transfected in COS cells (Gerald et al., 1995; Rose et al., 1995) . The reasons for this remain unclear. This may be tentatively ascribed to species differences in the properties of Y 2 receptor and/or to differences in G protein composition or availability in the gut versus the brain. It is clear from this study that human small intestine is equipped with a Y 2 receptor that is 100% homologous to the human brain Y 2 receptor and exhibits a PYYpreferring profile when expressed in CHO cells (see Fig. 9 ). The concept of PYY preference (Laburthe et al., 1986; Laburthe, 1991) can probably be extended to Y 2 and/or Y 1 receptors in many tissues including human adipose tissue (Castan et al., 1993) , mouse kidney , and human (Cox and Tough, 1995) , rat, and mouse (Holliday et al., 2000) gastrointestinal epithelia. It may be functionally relevant to peripheral targets that have access to both NPY released from nerve endings and blood-borne PYY. Finally, it is worth pointing out that although the present study demonstrates that the PYY-preferring receptor in small intestine is a Y 2 receptor, we cannot strictly exclude that one or more PYYpreferring but still-unidentified receptors exist in mammals.
In conclusion, the present work demonstrates that the socalled PYY-preferring receptor mediating inhibition of small intestinal secretion by PYY or NPY is a peripheral Y 2 receptor. This demonstration puts an end to previous suggestions regarding the existence of a PYY-preferring receptor subtype in small intestine, which would represent an additional Y receptor. It also indicates that the potent and long-lasting proabsorptive and antisecretory PYY 22-36 analogs recently developed for intestinal PYY receptor (Balasubramaniam et al., 2000) may have broader value as Y 2 receptor agonists in various tissues. Whether other putative NPY receptor subtypes, such as Y 3 receptor (Michel et al., 1998) , grant an individual receptor status remains to be determined.
